普利特(002324.SZ):LCP薄膜全系列產品目前均已達到可量產狀態
格隆匯7月23日丨普利特(002324.SZ)於近期投資者關係活動表示,公司LCP樹脂佈局涵蓋I型、II型、III型樹脂,實現注塑級、薄膜級、纖維級樹脂全覆蓋;公司的LCP薄膜全系列產品目前均已達到可量產狀態。公司目前是全球唯一一家同時具備LCP樹脂合成、改性、薄膜和纖維技術以及量產能力的企業。公司經過17年自主開發及產業整合,在LCP領域實現全產業鏈佈局,目前具有每年4000噸LCP樹脂聚合產能、5000噸LCP共混改性生產能力,300萬平方米LCP薄膜生產能力,以及1000噸(1000D)LCP纖維的生產能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.